MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Krystal Biotech Inc

Gesloten

SectorGezondheidszorg

177.58 -1.85

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

169.85

Max

180.03

Belangrijke statistieken

By Trading Economics

Inkomsten

18M

45M

Verkoop

7.3M

91M

K/W

Sectorgemiddelde

59.9

63.778

EPS

1.53

Winstmarge

49.901

Werknemers

275

EBITDA

12M

43M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+20.52% upside

Dividenden

By Dow Jones

Volgende Winsten

5 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

232M

5.3B

Vorige openingsprijs

179.43

Vorige sluitingsprijs

177.58

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Krystal Biotech Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

3 apr 2025, 23:04 UTC

Top Nieuws

JPMorgan Raises Risk of U.S., Global Recession to 60%

3 apr 2025, 22:40 UTC

Belangrijke Marktbewegers

Aldeyra Shares Fall on FDA Complete Response Letter for Dry Eye Disease Drug

3 apr 2025, 22:18 UTC

Acquisities, Fusies, Overnames

Quantum Corp. Gets Strategic Investment, Names New Financial Chief

3 apr 2025, 18:51 UTC

Acquisities, Fusies, Overnames

Capital One, Discover Merger Clears Regulatory Hurdle, Sources Tell The New York Times

3 apr 2025, 23:43 UTC

Marktinformatie

Gold Steady, Supported by Potential Safe-Haven Demand -- Market Talk

3 apr 2025, 23:41 UTC

Marktinformatie

Nikkei May Fall as U.S. Tariffs Raise Concerns About Global Growth -- Market Talk

3 apr 2025, 22:22 UTC

Acquisities, Fusies, Overnames

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3 apr 2025, 22:21 UTC

Acquisities, Fusies, Overnames

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3 apr 2025, 21:43 UTC

Top Nieuws
Winsten

The Day Trump's Tariffs Shook Wall Street and Corporate America -- 5th Update

3 apr 2025, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

3 apr 2025, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

3 apr 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

3 apr 2025, 20:43 UTC

Marktinformatie

Plummeting Toronto Home Sales Reflect Trade, Political Uncertainty -- Market Talk

3 apr 2025, 20:34 UTC

Top Nieuws

Trump's Tariffs Were Supposed to Boost the Dollar, But Here's Why the Opposite Happened -- Heard on the Street -- 2nd Update

3 apr 2025, 20:23 UTC

Top Nieuws

Trump Tariffs Send Dow Industrials to 1600-Point Decline; Dollar Slumps -- WSJ

3 apr 2025, 20:15 UTC

Acquisities, Fusies, Overnames

Blackstone Life Sciences And Anthos Therapeutics Announce Novartis Has Completed The Acquisition Of Anthos Therapeutics In A Deal Valued At Up To $3.1B, With $925M Paid Upfront >BX

3 apr 2025, 19:55 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

3 apr 2025, 19:55 UTC

Marktinformatie

Dollar Weakens as Investors Seek Safety Elsewhere -- Market Talk

3 apr 2025, 19:21 UTC

Marktinformatie

Oil Futures Slide on U.S. Tariffs, OPEC+ Output Plan -- Market Talk

3 apr 2025, 19:15 UTC

Marktinformatie

U.S. Natural Gas Stays Focused on Weather, Storage -- Market Talk

3 apr 2025, 18:45 UTC

Marktinformatie

Market Talk Roundup: Latest on U.S. Politics

3 apr 2025, 18:45 UTC

Marktinformatie

Gold Drops In Tariff Fallout -- Market Talk

3 apr 2025, 18:39 UTC

Marktinformatie

U.S. Tariffs Could Give Natural Gas Edge Over Solar -- Market Talk

3 apr 2025, 18:38 UTC

Top Nieuws

Trump Tariffs Send Dow Industrials to 1400-Point Decline; Dollar Slumps -- WSJ

3 apr 2025, 18:30 UTC

Top Nieuws

Auto Industry Braces for Major Pain From Trump's Tariffs -- Analysis

3 apr 2025, 18:20 UTC

Marktinformatie

Uncertainty Still Roils Companies in Tariff Saga -- Market Talk

3 apr 2025, 18:18 UTC

Marktinformatie

Market Talk Roundup: Latest on U.S. Politics

3 apr 2025, 18:17 UTC

Marktinformatie

U.S. Workers Can't Match International Labor as Companies Consider Moving Supply Chains -- Market Talk

3 apr 2025, 18:04 UTC

Marktinformatie

US Sees More Job Openings in Construction, Transportation -- Market Talk

3 apr 2025, 17:55 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Krystal Biotech Inc Prognose

Koersdoel

By TipRanks

20.52% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 218.14 USD  20.52%

Hoogste 245 USD

Laagste 200 USD

Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor Krystal Biotech Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

8 ratings

7

Buy

1

Hold

0

Sell

Technische score

By Trading Central

174.58 / 188.61Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Krystal Biotech Inc

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.